Julie Charles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julie Charles has a total of 704 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Thérèse Leccia
Department of Dermatology, Grenoble University Hospital, Grenoble, France
21 shared publications - Caroline Aspord
Institute for Advanced Biosciences, Team: Immunology & Immunotherapy of Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Univ. Grenoble Alpes
11 shared publications - Laurence Chaperot
Université Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), Team Translational Immunology and Immunotherapy in Chronic Disease Grenoble France
10 shared publications Joel Plumas
University Grenoble Alpes, Grenoble, France
9 shared publications- Benoit Busser
Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB)
6 shared publications Isabelle Templier
Dermatology Unit, Univ. Grenoble Alpes, IAB, University Hospital of Grenoble, Grenoble, France
5 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Wiley in Immunology
- Vol. 179 (3) , 486-515
Metabolic Profiling of Circulating and Tumour‐Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients
Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour‐infiltrating CD4 + and CD8 + T cells of melanoma patients at a single‐cell level using the SCENITH method and targeted metabolomics. Circulating and tumour‐infiltrating T cells from patients displayed a decreased mitochondrial dependency associated with an enhanced glycolytic capacity and a skewed metabolic reprogramming upon stimulation. Such metabolic disturbances were linked to the activation status, immune checkpoint profile and functional orientation of T cells, underlining critical connections between T‐cell features and metabolic patterns. Targeted metabolomics within sorted CD4 + /CD8 + T cells identified a decrease in citrulline, cysteine and threonine within all subsets in patients, together with a sharp rise in sterol cholesterol CE(20:2) and ceramide dhCer(d18:0/22:0) within tumour‐infiltrating CD4 + T cells, and in glycerolipid DG(16:0/16:0) within CD8 + T cells in blood and tumour. We further outlined a metabolic‐checkpoint‐based signature composed of six genes coding enzymes/transporters connected to the imbalanced metabolites found within tumour‐infiltrating T cells ( LIPA , DGKA , GLUL , SLC38A1 , SLC7A7 , GCH1 ) that shape patients' clinical outcome. These findings outline the skewed bioenergetic profiles of T cells and depict metabolic checkpoints associated with immune subversion. Harnessing metabolic pathways is promising for developing innovative therapies to restore optimal anti‐tumour responses and improve clinical success.
- 4 August 2026
- Published by Wiley in Immunology
- Vol. 179 (3) , 486-515
Open AccessMetabolic Profiling of Circulating and Tumour‐Infiltrating T Cells Uncovers Bioenergetic Checkpoints Linked With Immune and Clinical Skewing in Melanoma Patients
Metabolism is critical for immune cell functions. Tumours shape their microenvironment to render it metabolically hostile for infiltrating immune cells. While targeting immunometabolism emerges as a promising way to reinvigorate anticancer immunity, a deeper understanding of the metabolic disturbances of immune cells is needed. Here, we explored how the metabolic status of T cells governs immune skewing from circulating and tumour‐infiltrating CD4 + and CD8 + T cells of melanoma patients at a single‐cell level using the SCENITH method and targeted metabolomics. Circulating and tumour‐infiltrating T cells from patients displayed a decreased mitochondrial dependency associated with an enhanced glycolytic capacity and a skewed metabolic reprogramming upon stimulation. Such metabolic disturbances were linked to the activation status, immune checkpoint profile and functional orientation of T cells, underlining critical connections between T‐cell features and metabolic patterns. Targeted metabolomics within sorted CD4 + /CD8 + T cells identified a decrease in citrulline, cysteine and threonine within all subsets in patients, together with a sharp rise in sterol cholesterol CE(20:2) and ceramide dhCer(d18:0/22:0) within tumour‐infiltrating CD4 + T cells, and in glycerolipid DG(16:0/16:0) within CD8 + T cells in blood and tumour. We further outlined a metabolic‐checkpoint‐based signature composed of six genes coding enzymes/transporters connected to the imbalanced metabolites found within tumour‐infiltrating T cells ( LIPA , DGKA , GLUL , SLC38A1 , SLC7A7 , GCH1 ) that shape patients' clinical outcome. These findings outline the skewed bioenergetic profiles of T cells and depict metabolic checkpoints associated with immune subversion. Harnessing metabolic pathways is promising for developing innovative therapies to restore optimal anti‐tumour responses and improve clinical success.
- 25 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116878
Survival outcomes of adjuvant therapy in resected stage III melanoma: results from a real-life cohort study (TAMARIS)
- 25 June 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 244, 116878
Survival outcomes of adjuvant therapy in resected stage III melanoma: results from a real-life cohort study (TAMARIS)
- 25 May 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 6 (4) , 285-295
Quoi de neuf en oncodermatologie en 2025 ?
- 25 May 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 6 (4) , 285-295
Quoi de neuf en oncodermatologie en 2025 ?
- 12 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
- 12 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A122-A123
Immunothérapie dans le mélanome en hospitalisation à domicile : enquête de satisfaction et retour d’expérience des centres français d’oncodermatologie
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A122-A123
Immunothérapie dans le mélanome en hospitalisation à domicile : enquête de satisfaction et retour d’expérience des centres français d’oncodermatologie
- 22 October 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (4) , 501-507
Natural History of Perianal Fistulising Lesions in Patients With Elderly-onset Crohn’s Disease: A Population-based Study
Introduction: Most studies of elderly-onset Crohn’s disease [CD; diagnosed in patients aged 60 or over] have described a mild course. However, data on the natural history of perianal fistulising CD [pfCD] in this population are scarce. In a population-based cohort study, we described the prevalence, natural history, and treatment of pfCD in patients with elderly-onset CD vs patients with paediatric-onset CD. Method: All patients diagnosed with CD at or after the age of 60 between 1988 and 2006, were included [n = 372]. Logistic regression, Cox models, and a nested case-control method were used to identify factors associated with pfCD. Results: A total of 34 elderly patients [9% of the 372] had pfCD at diagnosis. After a median follow-up of 6 years (interquartile range [IQR]: 3; 10), 59 patients [16%] had pfCD; the same prevalence [16%] was observed in paediatric-onset patients. At last follow-up, anal incontinence was more frequent in elderly patients with pfCD than in elderly patients without pfCD [22% vs 4%, respectively; p < 10–4]. Rectal CD at diagnosis was associated with pfCD: hazard ratio (95% confidence interval [CI] = 2.8 [1.6–5.0]). Although 37% of the patients received immunosuppressants and 17% received anti-tumour necrosis factor agents, 24% [14 out of 59] had a definitive stoma at last follow-up. Conclusion: During the first 6 years of disease, the prevalence of pfCD was similar in elderly and paediatric patients. Rectal involvement was associated with the appearance of pfCD in elderly-onset patients. Around a quarter of patients with elderly-onset CD will have a stoma. Our results suggest that treatment with biologics should be evaluated in these patients.
- 22 October 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 14 (4) , 501-507
Natural History of Perianal Fistulising Lesions in Patients With Elderly-onset Crohn’s Disease: A Population-based Study
Introduction: Most studies of elderly-onset Crohn’s disease [CD; diagnosed in patients aged 60 or over] have described a mild course. However, data on the natural history of perianal fistulising CD [pfCD] in this population are scarce. In a population-based cohort study, we described the prevalence, natural history, and treatment of pfCD in patients with elderly-onset CD vs patients with paediatric-onset CD. Method: All patients diagnosed with CD at or after the age of 60 between 1988 and 2006, were included [n = 372]. Logistic regression, Cox models, and a nested case-control method were used to identify factors associated with pfCD. Results: A total of 34 elderly patients [9% of the 372] had pfCD at diagnosis. After a median follow-up of 6 years (interquartile range [IQR]: 3; 10), 59 patients [16%] had pfCD; the same prevalence [16%] was observed in paediatric-onset patients. At last follow-up, anal incontinence was more frequent in elderly patients with pfCD than in elderly patients without pfCD [22% vs 4%, respectively; p < 10–4]. Rectal CD at diagnosis was associated with pfCD: hazard ratio (95% confidence interval [CI] = 2.8 [1.6–5.0]). Although 37% of the patients received immunosuppressants and 17% received anti-tumour necrosis factor agents, 24% [14 out of 59] had a definitive stoma at last follow-up. Conclusion: During the first 6 years of disease, the prevalence of pfCD was similar in elderly and paediatric patients. Rectal involvement was associated with the appearance of pfCD in elderly-onset patients. Around a quarter of patients with elderly-onset CD will have a stoma. Our results suggest that treatment with biologics should be evaluated in these patients.
- 1 June 2019
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 146 (6-7) , 487-491
Certolizumab
- 1 June 2019
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 146 (6-7) , 487-491
Certolizumab
- Open Access
- 28 March 2019
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 8 (1) , 8
Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with other treatments remains to be thoroughly documented. Here we report the case of a 33-year-old male with classical Hodgkin lymphoma who was successfully treated for lymphoma but experienced serious and eventually fatal multisystem organ failure following nivolumab administration and allogeneic stem cell transplantation. The patient was diagnosed with stage IIIa nodular sclerosing Hodgkin lymphoma. Originally treated by chemotherapy and autologous stem cell transplantation, he subsequently received two allogeneic stem cell transplants from matched and haplo-identical siblings upon successive disease recurrences. Nivolumab treatment was administered prior to the second allograft, after which complete remission of lymphoma was achieved (year 10), as evidenced by clinical and radiographic examination. However within the next 3 months, the patient went on to develop a constellation of symptoms affecting multiple organs, including acute pneumonia with no evidence of bacterial infection, widespread cutaneous eruptions on trunk and lower limbs, mucosal ulcerations, myositis, diarrhea and colitis. Further complications included hepatic cytolysis, acute renal failure, pancreatitis, as well as complete heart block. Some of these injuries being suggestive of graft-versus-host disease, the patient was administered immunosuppressive therapy (mycophenolate, steroids and polyvalent immunoglobulins), but died shortly afterwards. Tissue biopsies revealed extensive lymphocytic infiltration (mostly CD3 + T cells) in skin, liver, and most peculiarly in muscles, including the myocardium. Massive lymphoid-histiocytic infiltration of muscle fibers was accompanied by acute necrotizing myositis and endomysial inflammation. Multi-organ failure represents a rare but potentially fatal outcome of immune checkpoint blockade in patients receiving allogeneic stem cell grafts. Nivolumab may induce atypical immune-mediated tissue inflammation and damage, such as the extensive muscular polymyositis described here in a patient with Hodgkin lymphoma. Nivolumab might also worsen GVHD symptoms in the context of allogeneic stem cell transplantation. Irrespective of the actual pathological mechanisms, clinicians should be alerted to these fatal drug-related toxicities.
- 28 March 2019
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 8 (1) , 8
Open AccessMulti-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with other treatments remains to be thoroughly documented. Here we report the case of a 33-year-old male with classical Hodgkin lymphoma who was successfully treated for lymphoma but experienced serious and eventually fatal multisystem organ failure following nivolumab administration and allogeneic stem cell transplantation. The patient was diagnosed with stage IIIa nodular sclerosing Hodgkin lymphoma. Originally treated by chemotherapy and autologous stem cell transplantation, he subsequently received two allogeneic stem cell transplants from matched and haplo-identical siblings upon successive disease recurrences. Nivolumab treatment was administered prior to the second allograft, after which complete remission of lymphoma was achieved (year 10), as evidenced by clinical and radiographic examination. However within the next 3 months, the patient went on to develop a constellation of symptoms affecting multiple organs, including acute pneumonia with no evidence of bacterial infection, widespread cutaneous eruptions on trunk and lower limbs, mucosal ulcerations, myositis, diarrhea and colitis. Further complications included hepatic cytolysis, acute renal failure, pancreatitis, as well as complete heart block. Some of these injuries being suggestive of graft-versus-host disease, the patient was administered immunosuppressive therapy (mycophenolate, steroids and polyvalent immunoglobulins), but died shortly afterwards. Tissue biopsies revealed extensive lymphocytic infiltration (mostly CD3 + T cells) in skin, liver, and most peculiarly in muscles, including the myocardium. Massive lymphoid-histiocytic infiltration of muscle fibers was accompanied by acute necrotizing myositis and endomysial inflammation. Multi-organ failure represents a rare but potentially fatal outcome of immune checkpoint blockade in patients receiving allogeneic stem cell grafts. Nivolumab may induce atypical immune-mediated tissue inflammation and damage, such as the extensive muscular polymyositis described here in a patient with Hodgkin lymphoma. Nivolumab might also worsen GVHD symptoms in the context of allogeneic stem cell transplantation. Irrespective of the actual pathological mechanisms, clinicians should be alerted to these fatal drug-related toxicities.
- Open Access
- 1 February 2019
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (2) , 187-194
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
The programmed cell death 1 (PD-1) receptor inhibitors nivolumab and pembrolizumab have demonstrated superior efficacy compared with chemotherapy or the cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab in advanced melanoma, with a lower incidence of treatment-related grade 3/4 adverse events (AEs).1-6 In phase 2 and phase 3 trials, the combination of nivolumab and ipilimumab has demonstrated significantly longer progression-free survival and a higher objective response rate compared with ipilimumab alone.1,7-9
- 1 February 2019
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (2) , 187-194
Open AccessSurvival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
The programmed cell death 1 (PD-1) receptor inhibitors nivolumab and pembrolizumab have demonstrated superior efficacy compared with chemotherapy or the cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab in advanced melanoma, with a lower incidence of treatment-related grade 3/4 adverse events (AEs).1-6 In phase 2 and phase 3 trials, the combination of nivolumab and ipilimumab has demonstrated significantly longer progression-free survival and a higher objective response rate compared with ipilimumab alone.1,7-9
- 21 November 2018
- Published by Wiley in Contact Dermatitis
- Vol. 80 (3) , 184-186
Fixed drug eruption caused by fulvestrant confirmed by skin tests: First case
- 21 November 2018
- Published by Wiley in Contact Dermatitis
- Vol. 80 (3) , 184-186
Fixed drug eruption caused by fulvestrant confirmed by skin tests: First case